The MM27.7B1 monoclonal antibody specifically binds to the p28 subunit of mouse Interleukin-27 (IL-27 p28) that is also known as IL-27 alpha (IL-27α) or Interleukin-30 (IL-30). IL-27 p28 is a member of the IL-6/IL-12 family of cytokines. The IL-27 p28 subunit binds to the EBI3 (Epstein-Barr virus induced gene 3) protein to form heterodimeric Interleukin-27. IL-27 p28 is produced by macrophages and dendritic cells stimulated by inflammatory cytokines and ligands for Toll-like receptors (TLR). IL-27 binds to and transduces signal through surface IL-27 receptors (IL-27R) that are expressed by B cells and naive T cells and more highly expressed by NK cells and activated T cells. The IL-27R complex is comprised of gp130 (CD130) and WSX-1 (IL-27R alpha) subunits. IL-27 signals through IL-27R that activate the Jak/STAT signaling pathway resulting in the phosphorylation of Stat1 and Stat3. It acts in a proinflammatory manner to upregulate cellular T-bet transcription factor and surface IL-12R beta2 expression contributing to higher levels of IFN-γ and granzyme B expression. IL-27 exerts anti-inflammatory responses by suppressing the differentiation and proliferation of Th2 and Th17 cells. IL-27 p28 is reportedly produced and secreted independently of EBI3. It may inhibit the actions of IL-17 and other proinflammatory cytokines like IL-6. The MM27/7B1 antibody has been reported to neutralize IL-27 activity in vitro. Routine quality testing of mAb MM27.7B1 is performed via flow cytometry of intracellularly stained IL-27 p28-transfected cells.
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.
Konservierungsmittel
Without preservative
Handhabung
This preparation contains no preservatives, thus it should be handled under aseptic conditions.
Lagerung
4 °C
Informationen zur Lagerung
Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
Hall, Silver, Hunter: "The immunobiology of IL-27." in: Advances in immunology, Vol. 115, pp. 1-44, (2012) (PubMed).
Stumhofer, Tait, Quinn, Hosken, Spudy, Goenka, Fielding, OHara, Chen, Jones, Saris, Rose-John, Cua, Jones, Elloso, Grötzinger, Cancro, Levin, Hunter: "A role for IL-27p28 as an antagonist of gp130-mediated signaling." in: Nature immunology, Vol. 11, Issue 12, pp. 1119-26, (2010) (PubMed).
Stumhofer, Hunter: "Advances in understanding the anti-inflammatory properties of IL-27." in: Immunology letters, Vol. 117, Issue 2, pp. 123-30, (2008) (PubMed).
Morishima, Owaki, Asakawa, Kamiya, Mizuguchi, Yoshimoto: "Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 3, pp. 1686-93, (2005) (PubMed).
Yoshimoto, Okada, Morishima, Kamiya, Owaki, Asakawa, Iwakura, Fukai, Mizuguchi: "Induction of IgG2a class switching in B cells by IL-27." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 173, Issue 4, pp. 2479-85, (2004) (PubMed).
Hibbert, Pflanz, De Waal Malefyt, Kastelein: "IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells." in: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, Vol. 23, Issue 9, pp. 513-22, (2003) (PubMed).
Pflanz, Timans, Cheung, Rosales, Kanzler, Gilbert, Hibbert, Churakova, Travis, Vaisberg, Blumenschein, Mattson, Wagner, To, Zurawski, McClanahan, Gorman, Bazan, de Waal Malefyt, Rennick, Kastelein: "IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells." in: Immunity, Vol. 16, Issue 6, pp. 779-90, (2002) (PubMed).